Pilot investigations into the mechanistic basis for adverse effects of glucocorticoids in dysferlinopathy

• Published in: Skeletal muscle Vol. 14; no. 1; pp. 19 - 20
• Main Authors: Lloyd, Erin M, Crew, Rachael C, Haynes, Vanessa R, White, Robert B, Mark, Peter J, Jackaman, Connie, Papadimitriou, John M, Pinniger, Gavin J, Murphy, Robyn M, Watt, Matthew J, Grounds, Miranda D
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.08.2024; BMC
• Subjects: Adipose tissues; Animals; Complications and side effects; Dexamethasone; Dexamethasone - adverse effects; Dexamethasone - pharmacology; Disease Models, Animal; Dysferlin; Dysferlin - genetics; Dysferlin - metabolism; Dysferlinopathy; Gene expression; Gene mutations; Genes; Genetic aspects; Glucocorticoids; Glucocorticoids - adverse effects; Glucose metabolism; Glycogen; Histochemistry; Inflammation; Limb-girdle muscular dystrophy; Male; Membrane Proteins - genetics; Membrane Proteins - metabolism; Mice; Muscle Strength - drug effects; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Muscles; Muscular Dystrophies, Limb-Girdle - genetics; Muscular Dystrophies, Limb-Girdle - metabolism; Muscular Dystrophies, Limb-Girdle - pathology; Physiological aspects; Pilot Projects; Proteins; Skeletal muscle; Type 2 diabetes; Dexamethasone; Glucocorticoids; Glycogen; Limb-girdle muscular dystrophy; Dysferlin; Dysferlinopathy; Complement; Inflammasome; Adipocytes; Skeletal muscle
• ISSN: 2044-5040; 2044-5040
• DOI: 10.1186/s13395-024-00350-6

Dysferlinopathies are a clinically heterogeneous group of muscular dystrophies caused by gene mutations resulting in deficiency of the membrane-associated protein dysferlin. They manifest post-growth and are characterised by muscle wasting (primarily in the limb and limb-gridle muscles), inflammation, and replacement of myofibres with adipose tissue. The precise pathomechanism for dysferlinopathy is currently unclear; as such there are no treatments currently available. Glucocorticoids (GCs) are widely used to reduce inflammation and treat muscular dystrophies, but when administered to patients with dysferlinopathy, they have unexpected adverse effects, with accelerated loss of muscle strength. To investigate the mechanistic basis for the adverse effects of GCs in dysferlinopathy, the potent GC dexamethasone (Dex) was administered for 4-5 weeks (0.5-0.75 µg/mL in drinking water) to dysferlin-deficient BLA/J and normal wild-type (WT) male mice, sampled at 5 (Study 1) or 10 months (Study 2) of age. A wide range of analyses were conducted. Metabolism- and immune-related gene expression was assessed in psoas muscles at both ages and in quadriceps at 10 months of age. For the 10-month-old mice, quadriceps and psoas muscle histology was assessed. Additionally, we investigated the impact of Dex on the predominantly slow and fast-twitch soleus and extensor digitorum longus (EDL) muscles (respectively) in terms of contractile function, myofibre-type composition, and levels of proteins related to contractile function and metabolism, plus glycogen. At both ages, many complement-related genes were highly expressed in BLA/J muscles, and WT mice were generally more responsive to Dex than BLA/J. The effects of Dex on BLA/J mice included (i) increased expression of inflammasome-related genes in muscles (at 5 months) and (ii) exacerbated histopathology of quadriceps and psoas muscles at 10 months. A novel observation was pronounced staining for glycogen in many myofibres of the damaged quadriceps muscles, with large pale vacuolated myofibres, suggesting possible myofibre death by oncosis. These pilot studies provide a new focus for further investigation into the adverse effects of GCs on dysferlinopathic muscles.